|
 |
ProAmatineThis page contains recent news articles, when available, and an overview of ProAmatine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.In one case, a blood-pressure drug called ProAmatine was given conditional approval in 1996, but was never clearly proven to benefit patients. ... Wall Street Journal (blog) Wednesday's Our View: Money talks - Oct 28, 2009 Case in point: Investigators found the required study of the effectiveness of Shire Laboratories' low blood pressure treatment ProAmatine has gone ... SW Iowa News Редица непроверени лекарÑ?тва Ñ?е разпроÑ?транÑ?ват в СÐ?Щ - Oct 26, 2009 Повечето компании Ñ?пазват Ñ?роковете за изÑ?ледваниÑ?та, но при нÑ?кои не е така – типичен пример е лекарÑ?твото против ниÑ?ко кръвно налÑ?гане ProAmatine на Shire ... Econ.bg Postmarketing Studies for Shire's Proamatine Need Approval, FDA Says - Aug 14, 2007 The FDA has sent a letter to Shire Pharmaceuticals saying that it must get approval of postmarketing studies for its drug Proamatine, which is used to treat ... FDA news - FDA news (subscription) Postmarketing Studies for Shire's Proamatine Need Approval, FDA Says - Aug 13, 2007 The FDA has sent a letter to Shire Pharmaceuticals saying that it must get approval of postmarketing studies for its drug Proamatine, which is used to treat ... FDA news - FDA news (subscription) Postmarketing Studies for Shire's Drug Need Approval, FDA Says - Aug 20, 2007 The FDA has sent a letter to Shire Pharmaceuticals saying that it must get approval of postmarketing studies for its drug Proamatine, which is used to treat ... FDA news - FDA news (subscription) Drug Duo for Orthostatic Hypotension Spares Supine Blood Pressure - Feb 15, 2006 Proamatine (midodrine) has been the only drug shown in placebo-controlled ... Overall, Mestinon (60 mg) and Proamatine at (5 mg) were more effective than ... MedPage Today Merger and Acquisition Scenario - Jul 12, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 15, 2006 Target (Total: 32). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 8, 2008 Buyer (Total: 33). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target (Total: 5). Innohep (Tinzaparin Sodium); MGCD0103 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 Target (Total: 34). SPD535; ProAmatine (Midodrine); Pentasa (Mesalamine); Lialda (Mesalamine) ... ProAmatine (Midodrine). Digestive System ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 13, 2006 Buyer (Total: 32). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 26, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 11, 2006 Buyer (Total: 32). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 27, 2007 ProAmatine (Midodrine); Lialda (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... ProAmatine (Midodrine). Primary Pulmonary Hypertension ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 16, 2007 SPD535; ProAmatine (Midodrine); Lialda (Mesalamine); Pentasa (Mesalamine) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Markey: Accelerated drug review system is 'broken'.(Food and Drug … - Jun 1, 2005 The FDA in 1996 approved Proamatine to treat low blood pressure. Cabrey said Shire took over commitments for the drug after acquiring another company in ... Free with registration - Boston Globe - AccessMyLibrary.com Merger and Acquisition Scenario - Apr 7, 2007 Buyer (Total: 31). SPD535; ProAmatine (Midodrine); Pentasa (Mesalamine); Lialda (Mesalamine) ... ProAmatine (Midodrine). Digestive System ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 14, 2007 SPD535; ProAmatine (Midodrine); Pentasa (Mesalamine); Lialda (Mesalamine) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 26, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 27, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Cirrhosis and chronic liver failure: Part II. Complications and... - Sep 1, 2006 ...with oral midodrine (ProAmatine) and parenteral octreotide compared with ... Hepatorenal Midodrine (ProAmatine) and syndrome octreotide (Sandostatin) ... Free with registration - American Family Physician - AccessMyLibrary.com Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 2, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 29, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 22, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 26, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3) ... ProAmatine (Midodrine). Dermatology. Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Cirrhosis and chronic liver failure: Part II. Complications and... - Sep 1, 2006 ...with oral midodrine (ProAmatine) and parenteral octreotide compared with ... Hepatorenal Midodrine (ProAmatine) and syndrome octreotide (Sandostatin) ... $4.95 - American Family Physician - ECNext First-line treatment of patients with ascites (fluid accumulation in... - Dec 12, 2008 Drug therapy includes oral midodrine (ProAmatine) and octreotide (Sandostatin). Studies suggest that the vasoconstrictor drug terlipressin may be an ... New York Times Rehabilitative Management of Complications of Spinal Cord Injury - Dec 1, 2006 Some patients will require pharmacologic management with a-adrenergic agonist drugs, such as ephedrine and midodrine (ProAmatine). ... Psychiatric Times Is Midodrine Effective for Children with Vasovagal Syncope? - Jul 1, 2007 Midodrine (Proamatine) is a selective peripheral alpha-adrenergic agonist that can effectively treat vasovagal syncope in adults. ... AAFP News Now Drug firm Shire launches clinical trial site - Oct 29, 2007 ...available on Adderall XR® (mixed amphetamine salts), DaytranaR® (methylphenidate transdermal system), Lialda® (Mesalazine) and ProAmatine® (midodrine). Pharmacy Europe Shire Plc - Jun 19, 2006 ...jor drugs also include Agrylin and Xagrid for thrombocytosis; Proamatine and Amatine for symptomatic or-. thostatic hypotension; Fosrenol for ... $35.00 - Stock Reports - Standard & Poor's New FDA Orphan Drugs: Droxidopa, LX201, Marqibo - Jan 30, 2007 Midodrine (ProAmatine tablets, made by Shire Laboratories, Inc) is currently the only FDA-approved treatment for orthostatic hypotension. ... Medscape Merger and Acquisition Scenario - Dec 16, 2006 Buyer (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Cirrhosis In-Depth Report - Mar 8, 2008 Drug therapy includes oral midodrine (ProAmatine) and octreotide (Sandostatin). Studies suggest that the vasoconstrictor drug terlipressin may be an ... New York Times Merger and Acquisition Scenario - Nov 25, 2006 Target (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 15, 2006 Target (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 Buyer (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Target (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Buyer (Total: 30). ProAmatine (Midodrine); Mesavance/SPD 476 (Mesalamine); Pentasa (Mesalamine); Zeffix (Lamivudine) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target. Cetirizine Hydrochloride; Metroprolol Tartrate; Atenolol ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target. Cyproheptadine HCl; Fluticasone Propionate Nasal Spray ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Buyer (Total: 26). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target (Total: 13). Integrilin (Eptifibatide Injection) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 20, 2008 Buyer (Total: 26). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target (Total: 184) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target. Chore Boy; Cutex; Denorex; Prell. Business Relationship Summary: ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 6, 2008 SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target. Twinject Epinephrine Auto-Injector; Rondec Syrup/Rondec Oral Drops ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Buyer (Total: 26). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target (Total: 113) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Target (Total: 26). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Buyer. Quantitative Diagnostics Laboratories, Inc. (QDL) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 5, 2008 Target (Total: 25). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Buyer. Merial Group Ltd. Rosetta Elucidator System ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 1, 2008 Buyer (Total: 26). SPD535; ProAmatine (Midodrine); Juvista (Human TGFbeta3); Lialda (Mesalamine). Target (Total: 93). Ethex Hyoscyamine Sulfate Series ... $250.00 - Revere Reports - Revere |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |